FDA Accord With Drugmakers Raises User Fees 6% to Renew Law

Drugmakers such as Pfizer Inc. and Eli Lilly & Co. agreed with regulators on a 6 percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.